Cysteamine (oral)

Cysteamine (oral)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Cysteamine (oral) is {{{aOrAn}}} Renal-Urologic agent that is FDA approved for the treatment of nephropathic cystinosis in children and adults.. Common adverse reactions include Finding of odor of skin, rash, abdominal pain, breath smells unpleasant, diarrhea, loss of appetite, nausea, vomiting, dizziness, headache, lethargy and fever.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indication

CYSTAGON® is indicated for the management of nephropathic cystinosis in children and adults.

Dosage

New patients should be started on ¼ to 1/6 of the maintenance dose of CYSTAGON®. The dose should then be raised gradually over four to six weeks to avoid intolerance.

The recommended CYSTAGON® maintenance dose for children up to age 12 years is 1.30 grams/m2/day of the free base, given in four divided doses. Intact CYSTAGON® capsules should not be administered to children under the age of approximately six years due to the risk of aspiration. CYSTAGON® capsules may be administered to children under the age of approximately six years by sprinkling the capsule contents over food. Patients over age 12 and over 110 pounds weight should receive 2.0 grams/day, divided four times daily.

If a dose is missed, it should be taken as soon as possible. If it is within two hours of the next dose, skip the missed dose and go back to the regular dosing schedule. Do not double dose.

When CYSTAGON® is well tolerated, the goal of therapy is to keep leukocyte cystine levels below 1 nmol/½ cystine/mg protein five to six hours following administration of CYSTAGON®. Patients with poorer tolerability still receive significant benefit if white cell cystine levels are below 2 nmol/½ cystine/mg protein. The CYSTAGON® dose can be increased to a maximum of 1.95 grams/m2/day to achieve this level. The dose of 1.95 grams/m2/day has been associated with an increased rate of withdrawal from treatment due to intolerance and an increased incidence of adverse events.

Cystinotic patients taking cysteamine hydrochloride or phosphocysteamine solutions may be transferred to equimolar doses of CYSTAGON® capsules.

The recommended maintenance dose of 1.30 grams/m2/day can be approximated by administering CYSTAGON® according to the following table, which takes surface area as well as weight into consideration.

This image is provided by the National Library of Medicine.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Cysteamine in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Cysteamine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Cysteamine (oral) FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Cysteamine in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Cysteamine in pediatric patients.

Contraindications

There is limited information regarding Cysteamine (oral) Contraindications in the drug label.

Warnings

There is limited information regarding Cysteamine (oral) Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Cysteamine (oral) Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Cysteamine (oral) Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Cysteamine (oral) Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Cysteamine (oral) in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Cysteamine (oral) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Cysteamine (oral) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Cysteamine (oral) in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Cysteamine (oral) in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Cysteamine (oral) in geriatric settings.

Gender

There is no FDA guidance on the use of Cysteamine (oral) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Cysteamine (oral) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Cysteamine (oral) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Cysteamine (oral) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Cysteamine (oral) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Cysteamine (oral) in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Cysteamine (oral) Administration in the drug label.

Monitoring

There is limited information regarding Cysteamine (oral) Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Cysteamine (oral) and IV administrations.

Overdosage

There is limited information regarding Cysteamine (oral) overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Cysteamine (oral) Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Cysteamine (oral) Mechanism of Action in the drug label.

Structure

There is limited information regarding Cysteamine (oral) Structure in the drug label.

Pharmacodynamics

There is limited information regarding Cysteamine (oral) Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Cysteamine (oral) Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Cysteamine (oral) Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Cysteamine (oral) Clinical Studies in the drug label.

How Supplied

There is limited information regarding Cysteamine (oral) How Supplied in the drug label.

Storage

There is limited information regarding Cysteamine (oral) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Cysteamine (oral) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Cysteamine (oral) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Cysteamine (oral) Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Cysteamine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Cysteamine (oral) Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Cysteamine (oral) Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.